{"entity":{"id":"jmt101","kind":"drug","name":"JMT101","aka":[],"tldr":"JMT101 is an experimental monoclonal antibody from Shanghai JMT-Bio in phase 3 trials for non-small-cell lung cancer, aimed at EGFR.","summary":"JMT101 is a monoclonal antibody developed by Shanghai JMT-Bio. Its target is EGFR (the sponsor names EGFR). The sponsor states: JMT101 is a recombinant humanised anti-EGFR monoclonal antibody, given intravenously (6 mg/kg every two weeks) in combination with osimertinib versus osimertinib alone in EGFR-mutant non-small cell lung cancer. ClinicalTrials.gov describes the intervention as: JMT101 is a recombinant humanized anti-EGFR monoclonal antibody. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06735391 (A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations), in non-small-cell lung cancer. The largest, NCT06735391, plans to enrol 516 participants with primary completion expected 2026-09-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of JMT101","url":"https://clinicaltrials.gov/search?intr=JMT101"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":[],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06735391"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"monoclonal antibody","mechanism":"JMT101 is a recombinant humanised anti-EGFR monoclonal antibody, given intravenously (6 mg/kg every two weeks) in combination with osimertinib versus osimertinib alone in EGFR-mutant non-small cell lung cancer.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/jmt101/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}],"trial":[{"id":"nct06735391","kind":"trial","name":"A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations","route":"/trials/nct06735391/"},{"id":"nct06319313","kind":"trial","name":"Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer","route":"/trials/nct06319313/"},{"id":"nct07134205","kind":"trial","name":"The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer","route":"/trials/nct07134205/"}]}}